Skip to content

Mystical experience

Profound states of unity and self-transcendence, and their measured role as mediators of therapeutic outcomes.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Mystical experience, mystical-type experience, ego dissolution, unitive experience, peak experience, then ranked by relevance.

Research consistently shows that classic psychedelics like psilocybin can reliably occasion mystical-type experiences, characterized by unity, noetic quality, sacredness, positive mood, transcendence of time/space, and ineffability. These experiences are robustly associated with enduring positive changes in well-being, personality (increased openness), and therapeutic outcomes for conditions such as cancer-related distress, depression, anxiety, and addiction, with the mystical experience often mediating these benefits. However, most studies have small, homogeneous samples and many are open-label, limiting generalizability and causal certainty.

Confidence in the evidence

Moderate
  • Multiple double-blind RCTs and a systematic review consistently show psilocybin can induce mystical experiences and that these experiences predict positive outcomes.
  • Sample sizes are generally small (e.g., 18–36 in key experimental studies, 29 in the cancer RCT), limiting statistical power and generalizability.
  • Several studies are open-label or lack active placebo controls, increasing risk of expectancy bias.
  • The evidence is highly consistent in direction across diverse designs (RCTs, observational, qualitative) and populations (healthy volunteers, patients with cancer, smokers).
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial 2016
Supports

Psilocybin produced immediate and sustained improvements in anxiety and depression, and the psilocybin-induced mystical experience mediated these therapeutic effects.

RCT Sample size: 29

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. 2011
Supports

Psilocybin at 20 and 30 mg/70 kg produced mystical-type experiences in 72% of volunteers, with persisting positive changes in attitudes, mood, and behavior at 14 months.

RCT Sample size: 18

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness 2011
Supports

Psilocybin-occasioned mystical experiences led to significant increases in the personality domain of Openness that remained elevated more than 1 year later.

RCT

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later 2008
Supports

At 14-month follow-up, 58% rated the psilocybin experience among the five most personally meaningful and 67% among the five most spiritually significant experiences of their lives, with mystical experience mediating these ratings.

RCT Sample size: 36

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin 2015
Supports

The MEQ30 was validated and latent variable scores positively predicted persisting changes in attitudes, behavior, and well-being attributed to psilocybin.

observational Sample size: 184

Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. 2016
Unclear

Increased global functional connectivity correlates with LSD-induced ego dissolution.

observational

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors 2017
Supports

High-dose psilocybin produced greater acute and persisting effects than low-dose, with large positive changes in interpersonal closeness, gratitude, life meaning, and other measures at 6 months, mediated by mystical experience and meditation practice.

RCT Sample size: 75

Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. 2019
Supports

Classic psychedelics occasion mystical experiences characterized by a strong sense of unity, and naturalistic use is associated with positive mental health and prosocial outcomes.

review

Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction 2015
Supports

80% of participants demonstrated biologically verified smoking abstinence at 6 months, and abstainers scored significantly higher on mystical experience, suggesting a mediating role.

observational Sample size: 15

Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin 2012
Supports

Factor analysis of the MEQ revealed a four-factor structure (unity/noetic/sacredness, positive mood, transcendence of time/space, ineffability) with good reliability and validity.

observational Sample size: 1602

Religious and Mystical Experiences as Artifacts of Temporal Lobe Function: A General Hypothesis 1983
Unclear

Mystical and religious experiences are hypothesized to be evoked by transient electrical microseizures within deep structures of the temporal lobe.

theoretical

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review 2022
Supports

10 of 12 studies found a significant association between mystical experience and symptom reduction in psychedelic therapy for cancer-related distress, substance use disorder, and depression.

review

Self unbound: ego dissolution in psychedelic experience 2017
Unclear

Ego dissolution is explained by predictive processing principles, suggesting the self-model is a useful fiction that does not correspond to a real entity.

theoretical

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. 2018
Unclear

Classic hallucinogens and mystical experiences: phenomenology and neural correlates.

review

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? 2015
Supports

Evidence suggests a relationship between subjective experiences (peak experiences, afterglow) and therapeutic success with psychedelics.

review

Mystical Experiences as Catalysts in Ketamine-Assisted Psychotherapy: A Case Study 2026
Supports

Greater therapeutic gains followed ketamine sessions with higher mystical experience scores, and the patient attributed improvements to the psychological and spiritual impact.

qualitative Sample size: 1

How People Describe Their Mystical Experiences: Analyzing Language, Narrative, and Digital Expression 2026
Mixed

Social media users share detailed narratives of mystical experiences, challenging the notion of ineffability, and community identity shapes how experiences are framed.

observational

The Architecture of Ego Dissolution: A Mechanical-First Evaluation of N,N-Dimethyltryptamine at the Sigma-1 and 5-HT2A Interfaces 2026
Unclear

Evaluation of N,N-Dimethyltryptamine at the Sigma-1 and 5-HT2A interfaces.

theoretical

Optimizing music for psychedelic-assisted therapy: Examining contemporary practices, traditional entheogenic rituals, and musically-induced peak experiences 2026
Unclear

Conflicting musical features across modern PAT, traditional rituals, and musically-induced peak experiences suggest music should be tailored to the drug, individual, and desired experience.

review

Integrating the Mystical Experience Questionnaire Into a Broader Psychometric Framework: English Validation of the Psychedelic Experience Scale and Comparison of Psilocybin and LSD Sessions Across Two Controlled Settings. 2026
Supports

Six of eight subscales of the English Psychedelic Experience Scale (including mystical factors) show high internal consistency, supporting the factor structure.

observational Sample size: 280

DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality 2026
Unclear

Relations between DMT, psychosis model, therapy model, and mystical experiences and positive emotionality.

theoretical

On the ineffability and the noetic quality of mystical experiences 2026
Unclear

Using Wittgenstein's framework, mystical experiences are placed outside the limits of language, but have pragmatic and subjective value for religious life.

theoretical

A cross-sectional survey on depersonalization/derealization and meditation-induced alterations of the self. 2026
Mixed

Meditation-induced DPDR-like states are phenomenologically similar but experienced as more positive and spiritually meaningful than those from trauma or cannabis.

observational Sample size: 121

Does Psychological Flexibility Correlate with Mystical Experiences: A Machine Learning Approach Including State of Surrender, Near-Death Experiences, and Psilocybin Consumption. 2026
Supports

State of Surrender, experiential acceptance, cognitive defusion, and present-moment awareness emerged as robust predictors of mystical experiences.

observational Sample size: 150

Understanding mystical experiences through the lens of entropy: introduction to the special issue on ‘mystical entropy’ 2026
Unclear

Introduction to a special issue on 'mystical entropy'.

theoretical

Points of agreement

  • Psilocybin and other classic psychedelics can reliably induce mystical-type experiences in controlled settings.
  • Mystical experiences are consistently associated with enduring positive changes in well-being, attitudes, and behavior.
  • The mystical experience often mediates therapeutic outcomes in conditions like anxiety, depression, and addiction.
  • The MEQ30 is a validated and reliable tool for measuring mystical experiences.

Conflicts

  • One study suggests mystical experiences may be artifacts of temporal lobe microseizures, while others treat them as psychologically meaningful and therapeutic.
  • The role of ineffability is contested: some studies find detailed narratives online, while philosophical analysis argues mystical experiences lie outside language.
  • Music features that optimize mystical experiences in PAT differ from those in traditional rituals and musically-induced peak experiences.

Gaps

  • Most studies have small, homogeneous samples lacking diversity in gender, ethnicity, and socioeconomic status.
  • Many studies are open-label or lack active placebo controls, increasing risk of bias.
  • Long-term durability of effects beyond 14 months is rarely assessed.
  • Predictors of mystical experience intensity and methods to minimize anxiety during sessions are underexplored.
  • The neural mechanisms underlying mystical experiences are not fully characterized.
Browse these studies in the library
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Mystical experience, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Mystical experience or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: March 2026 →

1,531 articles · 502 from the last two years · 914,304 participants across 517 studies reporting sample size

Common study designs

review 128 historical analysis 61 observational cohort 66 cross-sectional survey 77 theoretical or philosophical paper 526

Research

Synthesize the evidence → Search all →

New insights into the clinical and nonclinical effects of psychedelic substances: an integrative review

Matthias Forstmann, Christina Sagioglou preprint

After a long period of stagnation, research on psychedelic substances like LSD, psilocybin, and DMT has revived over the last decade, with major programs in Europe and the United States. This review summarizes recent insights into their potential for treating mental health disorders, effects on recreational users, and underlying neurological and cognitive processes. It covers the history of psychedelic research, objective and subjective effects, prevalence and correlates of use, and potential for harm. The review examines clinical benefits for major depression, anxiety, and substance use disorders, along with proposed neural and cognitive mechanisms. It also discusses effects on healthy subjects, including psychological wellbeing, personality changes, nature relatedness, and creativity, and concludes with long-term effects of single experiences.

DOI: 10.31234/osf.io/2489x

Psychopathological descriptive model of hallucinogenic/psychedelic drugs effect in the treatment of depression and addictions

Nestor Girala

The efficacy of hallucinogenic drugs (ayahuasca, psilocybin, LSD, ketamine) in treating depression and addictions is accompanied by intense emotional states and mystical-type experiences, including feelings of oneness, transcendence, ineffability, and awe. These common psychopathological elements may mediate the drugs' therapeutic action. The paper reviews literature on subjective experiences during such treatments and compares them with other life-changing experiences, discussing the evolutionary value of these emotions for group cohesiveness and the recalibration of cognitions and emotions.

DOI: 10.14293/s2199-1006.1.sor-.ppfvg0c.v1

Measurement of the impact of orgasmic meditation on mystical experience

Vivian Siegel, Benjamin Emmert-Aronson

During orgasmic meditation (OM), a partnered practice involving clitoral stroking, participants report moderate to strong mystical experiences as measured by the Mystical Experience Questionnaire (MEQ30). In a first study, 62% of respondents recalling a single powerful OM reported a "complete mystical experience," with women reporting slightly stronger responses than men. In a second study with experienced practitioners reporting after their next OM, 23% reported a "complete mystical experience." The MEQ total score was more strongly correlated between partners than with the role of stroker or strokee, suggesting that the shared experience, rather than the specific role, drives the mystical quality. Whether brain activity during OM resembles that of other mystical experiences remains unknown.

DOI: 10.31231/osf.io/ug6vh

Individual differences in the pharmacokinetic profiling of Δ9-THC may be associated with differential motivational effects of Δ9-THC on cognitive performance

Teneisha M. Myers, Noah C. Neverette, Aaron S. Devanathan et al. preprint

Acute restraint stress and THC did not impair working memory in rats. However, a 3 mg/kg dose of THC disrupted motivation-related task engagement in some rats, while others were unaffected. Those that stopped responding had higher plasma THC and metabolite concentrations than those that continued. Individual differences in THC metabolism may explain why some people experience adverse cognitive or motivational effects after cannabis use, while others do not.

DOI: 10.1101/2025.09.30.679373

A Cross-Sectional Survey on Depersonalization/Derealization and Meditation-Induced Alterations of the Self

Erola Pons, Julieta Galante, Axel Lindner preprint

Meditation can trigger states phenomenologically similar to depersonalization/derealization (DPDR), but these experiences are typically rated as more positive, welcome, and spiritually meaningful than DPDR triggered by trauma, stress, or cannabis. In a cross-sectional survey comparing 60 people whose DPDR-like experiences came from meditation with 61 whose came from other triggers, the two groups scored similarly on the Cambridge Depersonalisation Scale but differed on measures of mysticism, ego dissolution, challenging experiences, and mindfulness. Most participants in both groups described their experiences as mixed, yet the meditation group rated them as much more positive. The findings suggest that contemplative approaches could inform clinical support for DPDR and that guidance is needed within meditation settings.

DOI: 10.31234/osf.io/6kyz9_v1

Shared Neurobiological and Computational Mechanisms of Psychedelic, Contemplative, and Fasting-Induced Mystical Experience

Alex Jinich-Diamant preprint

Mystical states induced by psychedelics, meditation, or fasting all converge on the same brain state: a transient near-critical regime. Serotonergic psychedelics relax top-down priors by sensitizing layer 5 pyramidal neurons; open-monitoring meditation elevates cortical entropy through altered thalamocortical connectivity; caloric restriction destabilizes the default mode network by attenuating metabolic support for high-level attractors. The depth of the mystical state, not the method of induction, predicts lasting therapeutic benefit, suggesting conscious experience itself is the mechanistic agent of change. This framework proposes that near-critical dynamics may allow field-theoretic and quantum-coherent contributions to consciousness to become detectable.

DOI: 10.31234/osf.io/km8hr_v2

Transdiagnostic conceptualization of schizophrenia and autism spectrum disorder. An integrative framework of minimal self disturbance

Ágota Vass, Gábor Csukly, Kinga Farkas 16 citations preprint

Autism spectrum disorder and schizophrenia share a disturbance in the minimal sense of self—a basic, pre-reflective awareness of being a subject of experience. This common feature cuts across diagnostic boundaries and may help explain overlapping symptoms. The authors propose a framework linking neural, cognitive, and phenomenological levels to study this self-disturbance. They argue that the neural correlates of minimal selfhood can be more reliably identified during meditation than during rest, because meditation amplifies present-focused inward attention while reducing reflective mind-wandering. This approach aligns with efforts to find biomarkers for psychopathology and to move beyond traditional diagnostic categories toward a model that takes self-experience seriously.

DOI: 10.31234/osf.io/vfuzh

ScholarOne - Limitless Experience through Limited Consumption: Psychedelics, Mystical Mindfulness, and Sustainable Corporate Leadership Development

Joshua Nunziato

Mindfulness, defined as non-focal awareness of consciousness itself, can be cultivated for corporate leadership development. Mystical mindfulness, integrating reflective mystical experience with everyday mindfulness, provides direct intuitive awareness of consciousness as an infinite source of experience mediated through finite bodies. A guided high-dose psychedelic trip can facilitate the insight that limited consumption—consistent with human health, equitable resource distribution, and biospheric regeneration—can enable limitless experiential opportunities. Decoupling tangible resource consumption growth from the growth of capabilities for producing and enjoying new experiences is possible and necessary. This recognition can orient leaders to create businesses addressing the unsustainability crisis.

DOI: 10.31124/advance.23710375

Can a Mystical Experience be Emulated by AI-Generated Rationality?

Mengjiao Yin

Artificial intelligence can evoke feelings of sacredness in people, but only under certain conditions. Spiritual believers report lower perceived sacredness, service quality, and trust when they know AI is involved, while non-believers show no such difference. Oral conversation enhances perceived sacredness compared to touch-screen interaction. The type of question asked—open-ended or closed-ended—does not significantly affect sacred experiences. AI cannot possess spirituality but can effectively evoke subjective sacred experiences through carefully designed interaction contexts.

DOI: 10.31235/osf.io/eyp9c_v1

Mystical Experience and Global Revolution

Mike Sosteric

Religion and spirituality, often dismissed as reactionary or illusory since Marx, contain an authentic revolutionary core. Drawing on biographical examples, the paper argues that human spirituality is not a primitive holdover but essentially revolutionary. In the face of escalating global ecological, political, and economic crises, this core must be examined, recovered, and embraced as part of local and global strategies for transformation.

DOI: 10.31235/osf.io/ah45u

Clinical trials

All Mystical experience trials →